Your browser doesn't support javascript.
loading
Molecular Genomic Profiling of Melanocytic Nevi.
Colebatch, Andrew J; Ferguson, Peter; Newell, Felicity; Kazakoff, Stephen H; Witkowski, Tom; Dobrovic, Alexander; Johansson, Peter A; Saw, Robyn P M; Stretch, Jonathan R; McArthur, Grant A; Long, Georgina V; Thompson, John F; Pearson, John V; Mann, Graham J; Hayward, Nicholas K; Waddell, Nicola; Scolyer, Richard A; Wilmott, James S.
Afiliación
  • Colebatch AJ; Melanoma Institute Australia, The University of Sydney, New South Wales, Australia; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia. Electronic address: Andrew.colebatch@health.nsw.gov.au.
  • Ferguson P; Melanoma Institute Australia, The University of Sydney, New South Wales, Australia; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
  • Newell F; Queensland Institute of Medical Research, Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Kazakoff SH; Queensland Institute of Medical Research, Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Witkowski T; Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.
  • Dobrovic A; Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia; School of Cancer Medicine and Molecular Cancer Prevention Program, La Trobe University, Bundoora, Victoria, Australia; Department of Clinical Pathology, University of Melbourne, Parkville, Victoria, Australia.
  • Johansson PA; Queensland Institute of Medical Research, Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Saw RPM; Melanoma Institute Australia, The University of Sydney, New South Wales, Australia; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; Department of Melanoma and Surgical Oncology, Discipline of Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Austral
  • Stretch JR; Melanoma Institute Australia, The University of Sydney, New South Wales, Australia; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
  • McArthur GA; Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
  • Long GV; Melanoma Institute Australia, The University of Sydney, New South Wales, Australia; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • Thompson JF; Melanoma Institute Australia, The University of Sydney, New South Wales, Australia; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; Department of Melanoma and Surgical Oncology, Discipline of Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Austral
  • Pearson JV; Queensland Institute of Medical Research, Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Mann GJ; Melanoma Institute Australia, The University of Sydney, New South Wales, Australia; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; Centre for Cancer Research, Westmead Institute for Medical Research, The University of Sydney, Westmead, New South Wales, Australia
  • Hayward NK; Queensland Institute of Medical Research, Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Waddell N; Queensland Institute of Medical Research, Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Scolyer RA; Melanoma Institute Australia, The University of Sydney, New South Wales, Australia; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
  • Wilmott JS; Melanoma Institute Australia, The University of Sydney, New South Wales, Australia; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
J Invest Dermatol ; 139(8): 1762-1768, 2019 08.
Article en En | MEDLINE | ID: mdl-30772300
ABSTRACT
The benign melanocytic nevus is the most common tumor in humans and rarely transforms into cutaneous melanoma. Elucidation of the nevus genome is required to better understand the molecular steps of progression to melanoma. We performed whole genome sequencing on a series of 14 benign melanocytic nevi consisting of both congenital and acquired types. All nevi had driver mutations in the MAPK signaling pathway, either BRAF V600E or NRAS Q61R/L. No additional definite driver mutations were identified. Somatic mutations in nevi with higher mutation loads showed a predominance of mutational signatures 7a and 7b, consistent with UVR exposure, whereas nevi with lower mutation loads (including all three congenital nevi) had a predominance of the ubiquitous signatures 1 and 5. Two nevi had mutations in promoter regions predicted to bind E26 transformation-specific family transcription factors, as well as subclonal mutations in the TERT promoter. This paper presents whole genome data from melanocytic nevi. We confirm that UVR is involved in the etiology of a subset of nevi. This study also establishes that TERT promoter mutations are present in morphologically benign skin nevi in subclonal populations, which has implications regarding the interpretation of this emerging biomarker in sensitive assays.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Biomarcadores de Tumor / Regulación Neoplásica de la Expresión Génica / Sistema de Señalización de MAP Quinasas / Nevo Pigmentado Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Idioma: En Revista: J Invest Dermatol Año: 2019 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Biomarcadores de Tumor / Regulación Neoplásica de la Expresión Génica / Sistema de Señalización de MAP Quinasas / Nevo Pigmentado Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Idioma: En Revista: J Invest Dermatol Año: 2019 Tipo del documento: Article